Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYi Zhun ZhuXTXiwen TongBXBin Xu

Discussion

Loading...

Member takes

Overview

Prospective study shows high efficacy of DCIA±X regimen in treating relapsed/refractory AML, suggesting potential for effective salvage therapies.

Key Points

  • High complete remission rates of 81.8% were achieved with the DCIA±X regimen in treating R/R AML patients, indicating its robust efficacy.
  • The prospective cohort study enrolled 22 patients, with an overall response rate of 95.4%, highlighting the effectiveness of this treatment.
  • Assessment of gene mutations and chromosomal abnormalities in patients provided insights into the underlying biology of R/R AML.
  • Successful hematopoietic stem cell transplantation was performed in 63.6% of responders, suggesting strong translational potential post-treatment.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d372https://doi.org/10.1182/blood-2025-6989
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia2025
  2. 2Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes2025
  3. 3Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia2025
  4. 4Outcomes with liposomal daunorubicin/cytarabine – a single-center experience2025
  5. 510-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group2025 · 2 citations